Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia
- PMID: 2477044
- DOI: 10.1097/00002093-198903030-00004
Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia
Abstract
Patients with Alzheimer disease (AD, onset less than 65 years of age, n = 13) and senile dementia of the Alzheimer type (SDAT, onset greater than or equal to 65 years of age, n = 28) were investigated for cerebrospinal fluid (CSF) content of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxy-phenylglycol (MHPG) and compared with a group of controls (n = 26). A geriatric rating scale, the Gottfries-Bråne-Steen scale, was used to assess impairment of motor performance, intellectual and emotional functioning, and symptoms common in dementia disorders. The HVA levels in CSF were significantly lower in the AD group than in the SDAT group and controls. MHPG was slightly but significantly increased in the SDAT group when compared with the controls. The HVA and 5-HIAA concentrations were correlated negatively with impairment of motor performance in the SDAT group; 5-HIAA correlated positively with impaired performance in the AD group; and 5-HIAA/HVA ratios were correlated positively with the performance variables. HVA correlated significantly and negatively with "impaired wakefulness" and "inability to increase tempo" in the SDAT group. 5-HIAA and the ratio 5-HIAA/HVA correlated significantly and positively with some items measuring intellectual and emotional impairment. In the AD group, "anxiety" and "fear-panic" correlated positively with 5-HIAA and "restlessness" with MHPG. The data indicate qualitative differences in the CSF monoamine pattern between AD and SDAT.
Similar articles
-
CSF monoamine metabolites in old age dementias.Mol Chem Neuropathol. 1992 Feb-Apr;16(1-2):143-57. doi: 10.1007/BF03159966. Mol Chem Neuropathol. 1992. PMID: 1381590
-
Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.J Neurol Neurosurg Psychiatry. 1984 May;47(5):481-4. doi: 10.1136/jnnp.47.5.481. J Neurol Neurosurg Psychiatry. 1984. PMID: 6204017 Free PMC article.
-
CSF monoamine metabolites in schizophrenic patients.Acta Psychiatr Scand. 1982 Nov;66(5):350-60. doi: 10.1111/j.1600-0447.1982.tb06717.x. Acta Psychiatr Scand. 1982. PMID: 6184954
-
Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?Med Biol. 1985;63(1):1-17. Med Biol. 1985. PMID: 2582215 Review.
-
The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines.Int Psychogeriatr. 1990 Fall;2(2):99-122. doi: 10.1017/s1041610290000370. Int Psychogeriatr. 1990. PMID: 1713799 Review.
Cited by
-
Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms.Mol Psychiatry. 2021 Mar;26(3):897-906. doi: 10.1038/s41380-019-0437-x. Epub 2019 May 28. Mol Psychiatry. 2021. PMID: 31138892
-
Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.Neuropsychiatr Dis Treat. 2007;3(5):627-36. Neuropsychiatr Dis Treat. 2007. PMID: 19300592 Free PMC article.
-
The biological basis of behavioral symptoms in dementia.Issues Ment Health Nurs. 2000 Jan-Feb;21(1):91-107. doi: 10.1080/016128400248284. Issues Ment Health Nurs. 2000. PMID: 10839054 Free PMC article. Review.
-
Noradrenergic hyperactivity after partial fornix section: role in cholinergic dependent memory performance.Exp Brain Res. 1992;89(1):125-32. doi: 10.1007/BF00229009. Exp Brain Res. 1992. PMID: 1601090
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical